Liminatus Pharma (LIMN) amended and restated its definitive merger agreement with InnocsAI LLC to advance a transaction focused on oncology and next-generation cell therapy technologies. The announcement provides no deal economics or timelines, so near-term impact is likely limited unless additional terms are disclosed.
Liminatus Pharma (LIMN) amended and restated its definitive merger agreement with InnocsAI LLC to advance a transaction focused on oncology and next-generation cell therapy technologies. The announcement provides no deal economics or timelines, so near-term impact is likely limited unless additional terms are disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
